All In Biotech

Drug Trial Radar · NCT03566017

Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease

Open Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegunigalsidase Alfa (PRX-102) in Patients With Fabry Disease

Last checked: Nov 20, 2026Latest source record: Mar 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

97

Actual

Start

Sep 16, 2018

Primary completion

Jan 21, 2025

Study completion Jan 21, 2025

Sponsor

Lead sponsor
Chiesi Farmaceutici S.p.A.Industry
Sponsor type
Industry
First posted
Jun 21, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of CLI-06657AA1-04 (formerly PB-102-F60) was to evaluate the long-term safety, tolerability, and efficacy parameters of 1 mg/kg pegunigalsidase alfa administered intravenously every other week in adult Fabry patients who had successfully completed studies PB-102-F20, PB-102-F30, or at least 48 months in study PB-102-F03.

Conditions

  • Fabry Disease

Interventions

  • pegunigalsidase alfaDrug

    Recombinant human alpha galactosidase A

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-related Adverse EventsTime frame: From first ever infusion of pegunigalsidase alfa, which could have been in the parent study (PB-102-F01/F20/F30) or this extension study, CLI-06657AA1-04, until 90 days after the final dose visit for each participant. Mean individual exposure: 5.5 years

Locations

30 sites in 13 countries. Site status is shown where the registry gives one.

  • UAB Medicine

    Birmingham, Alabama

  • Phoenix Children's Hospital

    Phoenix, Arizona

  • University of California San Diego

    La Jolla, California

  • University of California Irvine Center

    Orange, California

  • University of Florida

    Gainesville, Florida

  • Emory University School of Medicine

    Atlanta, Georgia

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • Infusion Associates

    Grand Rapids, Michigan

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • Renal Disease Research Institute, LLC - Dallas

    Dallas, Texas

  • Institute of Metabolic Disease

    Dallas, Texas

  • University of Utah Hospitals & Clinics

    Salt Lake City, Utah

  • O+O Alpan LLC

    Fairfax, Virginia

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia

  • Capital District Health Authority

    Halifax, Nova Scotia, Canada

  • Vseobecna fakultni nemocnice v Praze

    Prague, Czech Republic, Czechia

  • Turku University Central Hospital

    Turku, Finland

  • Hospital Raymond-Poincaré

    Garches, France

  • Semmelweis Egyetem

    Budapest, Hungary

  • Azienda Ospedaliera Universitaria "Federico II"

    Naples, Via Pansini, Italy

  • Academisch Medisch Centrum

    Amsterdam, Netherlands

  • Haukeland University Hospital Klinisk Forskningspost

    Bergen, Norway

  • General Hospital Slovenj Gradec

    Slovenj Gradec, Slovenia

  • Hospital de Dia Quiron Zaragoza

    Zaragoza, Spain

  • Addenbrooke's Hospital

    Cambridge, United Kingdom

  • The Royal Free Hospital

    London, United Kingdom

  • University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital

    Edgbaston, Birmingham, United Kingdom

  • Salford Royal

    Salford, Greater Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.